Engineering Escherichia coli for soluble expression and single step purification of active human lysozyme

Journal of Biotechnology

Volumn 164, Issue 1, 2013, Pages 1-8

  Lamppa, John W ^a,c   Tanyos, Sam A ^a   Griswold, Karl E ^a,b  

^a DARTMOUTH COLLEGE   (United States)

^b Molecular and Cellular Biology Program   (United States)

^c NONE   (United States)

Author keywords

Bioreactor; Escherichia coli; Inhibitor of vertebrate lysozyme; Ivy; Lysozyme; Molecular chaperones; Soluble expression

Indexed keywords

BIOREACTORS; DRUG DELIVERY; ESCHERICHIA COLI; PURIFICATION;

BACTERIAL PATHOGENS; DEVELOPMENT AND TESTING; ESCHERICHIA COLI CELLS; INHIBITORY PROTEINS; MOLECULAR CHAPERONES; ONE-STEP PURIFICATION; SINGLE-STEP PURIFICATION; SOLUBLE EXPRESSION;

ENZYMES;

CHAPERONE; LYSOZYME;

ARTICLE; BIOREACTOR; CONTROLLED STUDY; ENZYME PURIFICATION; ESCHERICHIA COLI; GENETICS; MOLECULAR INTERACTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FOLDING;

BACTERIA (MICROORGANISMS); ESCHERICHIA COLI; HARNESS; HEDERA; VERTEBRATA;

EID: 84875088103     PISSN: 01681656     EISSN: 18734863     Source Type: Journal    
DOI: 10.1016/j.jbiotec.2012.11.007     Document Type: Article

References (52)

1. Abergel C., Monchois V., Byrne D., Chenivesse S., Lembo F., Lazzaroni J.-C., Claverie J.-M. Structure and evolution of the Ivy protein family, unexpected lysozyme inhibitors in Gram-negative bacteria. Proceedings of the National Academy of Sciences of the United States of America 2007, 104:6394-6399.
2. Barroso, J., 2012. Amending Annex II to Regulation (EC) No 1333/2008 of the European Parliament and of the Council as regards the use of lysozyme (E 1105) in beer. In: Official Journal of the European Union. Report No.: (LEX-FAOC112986). European Union. (05.09.12). http://www.google.com/url?sa=tamp;rct=jamp;q=amp;esrc=samp;source=webamp;cd=1amp;cad=rjaamp;ved=0CDEQFjAAamp;url=http%3A%2F%2Fwww.parlament.gv.at%2FPAKT%2FEU%2FXXIV%2FEU%2F07%2F67%2FEU_76714%2Fimfname_10023376.pdf&ei=EXeVUP3bC5K40QHfz4DgAQ&usg=AFQjCNF2EH7e9943bTKk1yvf3jmU0_IkFQ.
3. Bessette P.H., Åslund F., Beckwith J., Georgiou G. Efficient folding of proteins with multiple disulfide bonds in the Escherichia coli cytoplasm. Proceedings of the National Academy of Sciences 1999, 96:13703-13708.
4. Bhavsar T., Liu M., Hardej D., Liu X.J., Cantor J. Aerosolized recombinant human lysozyme ameliorates Pseudomonas aeruginosa-induced pneumonia in hamsters. Experimental Lung Research 2010, 36:94-100.
5. Bhavsar T., Liu M., Liu X.J., Cantor J. Aerosolized recombinant human lysozyme enhances the bactericidal effect of tobramycin in a hamster model of Pseudomonas aeruginosa-induced pneumonia. Experimental Lung Research 2011, 37:536-541.
6. Blake C.C.F., Koenig D.F., Mair G.A., North A.C.T., Phillips D.C., Sarma V.R. Structure of hen egg-white lysozyme-a 3-dimensional Fourier synthesis at 2A resolution. Nature 1965, 206:757-761.
7. Braun P., LaBaer J. High throughput protein production for functional proteomics. Trends in Biotechnology 2003, 21:383-388.
8. Busso D., Peleg Y., Heidebrecht T., Romier C., Jacobovitch Y., Dantes A., Salim L., Troesch E., Schuetz A., Heinemann U., Folkers G.E., Geerlof A., Wilmanns M., Polewacz A., Quedenau C., Bussow K., Adamson R., Blagova E., Walton J., Cartwright J.L., Bird L.E., Owens R.J., Berrow N.S., Wilson K.S., Sussman J.L., Perrakis A., Celie P.H. Expression of protein complexes using multiple Escherichia coli protein co-expression systems: a benchmarking study. Journal of Structural Biology 2011, 175:159-170.
9. Callewaert L., Masschalck B., Deckers D., Nakimbugwe D., Atanassova M., Aertsen A., Michiels C.W. Purification of Ivy, a lysozyme inhibitor from Escherichia coli, and characterisation of its specificity for various lysozymes. Enzyme and Microbial Technology 2005, 37:205-211.
10. Casaite V., Bruzyte S., Bukauskas V., Setkus A., Morozova-Roche L.A., Meskys R. Expression and purification of active recombinant equine lysozyme in Escherichia coli. Protein Engineering Design & Selection 2009, 22:649-654.
11. Donovan D.M. Bacteriophage and peptidoglycan degrading enzymes with antimicrobial applications. Recent Patents on Biotechnology 2007, 1:113-122.
12. Entzminger K.C., Chang C., Myhre R.O., McCallum K.C., Maynard J.A. The Skp chaperone helps fold soluble proteins in vitro by inhibiting aggregation. Biochemistry 2012, 51:4822-4834.
13. Fischer B., Perry B., Phillips G., Sumner I., Goodenough P. Physiological consequence of expression of soluble and active hen egg white lysozyme in Escherichia coli. Applied Microbiology and Biotechnology 1993, 39:537-540.
14. Fleming A. On a remarkable bacteriolytic element found in tissues and secretions. Proceedings of the Royal Society of London Series B: Containing Papers of a Biological Character 1922, 93:306-317.
15. Gill A., Scanlon T.C., Osipovitch D.C., Madden D.R., Griswold K.E. Crystal structure of a charge engineered human lysozyme having enhanced bactericidal activity. PLoS One 2011, 6:e16788.
16. Guzman L.M., Belin D., Carson M.J., Beckwith J. Tight regulation, modulation, and high-level expression by vectors containing the arabinose PBAD promoter. Journal of Bacteriology 1995, 177:4121-4130.
17. Hayano T., Hirose M., Kikuchi M. Protein disulfide isomerase mutant lacking its isomerase activity accelerates protein folding in the cell. FEBS Letters 1995, 377:505-511.
18. Higo J., Nakasako M. Hydration structure of human lysozyme investigated by molecular dynamics simulation and cryogenic X-ray crystal structure analyses: on the correlation between crystal water sites, solvent density, and solvent dipole. Journal of Computational Chemistry 2002, 23:1323-1336.
19. Horwich A.L., Apetri A.C., Fenton W.A. The GroEL/GroES cis cavity as a passive anti-aggregation device. FEBS Letters 2009, 583:2654-2662.
20. Ibrahim H.R., Aoki T., Pellegrini A. Strategies for new antimicrobial proteins and peptides: lysozyme and aprotinin as model molecules. Current Pharmaceutical Design 2002, 8:671.
21. Imoto T. Engineering of lysozyme. EXS 1996, 75:163-181.
22. Iwata T., Tanaka R., Suetsugu M., Ishibashi M., Tokunaga H., Kikuchi M., Tokunaga M. Efficient secretion of human lysozyme from the yeast, Kluyveromyces lactis. Biotechnology Letters 2004, 26:1803-1808.
23. Jolles P. Lysozymes: Model Enzymes in Biochemistry and Biology 1996, Birkhauser Verlag Basel, Boston, p. 449.
24. Kaiser C.M., Chang H.C., Agashe V.R., Lakshmipathy S.K., Etchells S.A., Hayer-Hartl M., Hartl F.U., Barral J.M. Real-time observation of trigger factor function on translating ribosomes. Nature 2006, 444:455-460.
25. Kiefhaber T. Kinetic traps in lysozyme folding. Proceedings of the National Academy of Sciences 1995, 92:9029-9033.
26. 2+ binding sites and its efficient refolding system from inclusion bodies. Protein Engineering 1998, 11:683-690.
27. Lake, L.R., 1998. Direct Food Substances Affirmed as Generally Recognized as Safe; Egg White Lysozyme. In: Federal Register Online via the Government Printing Office. Report No.: (21 CFR Part 184). (05.09.12). http://www.gpo.gov/fdsys/pkg/FR-1998-03-13/html/98-6571.htm.
28. Lee Y.C., Yang D. Determination of lysozyme activities in a microplate format. Analytical Biochemistry 2002, 310:223-224.
29. Levy R., Weiss R., Chen G., Iverson B.L., Georgiou G. Production of correctly folded Fab antibody fragment in the cytoplasm of Escherichia coli trxB gor mutants via the coexpression of molecular chaperones. Protein Expression and Purification 2001, 23:338-347.
30. Lu X.M., Jin X.B., Zhu J.Y., Mei H.F., Ma Y., Chu F.-J., Wang Y., Li X.-B. Expression of the antimicrobial peptide cecropin fused with human lysozyme in Escherichia coli. Applied Microbiology and Biotechnology 2010, 87:2169-2176.
31. Maga E.A., Shoemaker C.F., Rowe J.D., Bondurant R.H., Anderson G.B., Murray J.D. Production and processing of milk from transgenic goats expressing human lysozyme in the mammary gland. Journal of Dairy Science 2006, 89:518-524.
32. Makino T., Skretas G., Kang T.-H., Georgiou G. Comprehensive engineering of Escherichia coli for enhanced expression of IgG antibodies. Metabolic Engineering 2011, 13:241-251.
33. Maullu C., Lampis G., Desogus A., Ingianni A., Rossolini G.M., Pompei R. High-level production of heterologous protein by engineered yeasts grown in cottage cheese whey. Applied and Environment Microbiology 1999, 65:2745-2747.
34. Monchois V., Abergel C., Sturgis J., Jeudy S., Claverie J.-M. Escherichia coli ykfE ORFan gene encodes a potent inhibitor of C-type lysozyme. Journal of Biological Chemistry 2001, 276:18437-18441.
35. Parisien A., Allain B., Zhang J., Mandeville R., Lan C.Q. Novel alternatives to antibiotics: bacteriophages, bacterial cell wall hydrolases, and antimicrobial peptides. Journal of Applied Microbiology 2008, 104:1-13.
36. Perez-Perez J., Gutierrez J. An Arabinose-Inducible Expression Vector, PAR3 Compatible with ColE1-Derived Plasmids. Gene 1995, 158:141-142.
37. Perez-Perez J., Martinez-Caja C., Barbero J.L., Gutierrez J. DNAK/DNAJ supplementation improves the periplasmic production of human granulocyte-colony stimulating factor in Escherichia coli. Biochemical and Biophysical Research Communications 1995, 210:524-529.
38. Riesenberg D., Schulz V., Knorre W.A., Pohl H.D., Korz D., Sanders E.A., Ross A., Deckwer W.D. High cell density cultivation of Escherichia coli at controlled specific growth rate. Journal of Biotechnology 1991, 20:17-27.
39. Scanlon T.C., Gray E.C., Griswold K.E. Quantifying and resolving multiple vector transformants in S. cerevisiae plasmid libraries. BMC Biotechnology 2009, 9:95.
40. Scanlon T.C., Teneback C.C., Gill A., Bement J.L., Lamppa J.W., Weiner J.A., Leclair L.W., Griswold K.E. Enhanced antimicrobial activity of engineered human lysozyme. ACS Chemical Biology 2010, 5:809-818.
41. Schlorb C., Ackermann K., Richter C., Wirmer J., Schwalbe H. Heterologous expression of hen egg white lysozyme and resonance assignment of tryptophan side chains in its non-native states. Journal of Biomolecular NMR 2005, 33:95-104.
42. Speijers, G., van Apeldoorn, M., 2012. National Institute of Public Health and Environmental Protection. (05.09.12). http://www.inchem.org/documents/jecfa/jecmono/v30je04.htm.
43. Swaminathan R., Ravi V.K., Kumar S., Kumar M.V.S., Chandra N. Lysozyme: a model protein for amyloid research. Advances in Protein Chemistry and Structural Biology 2011, vol. 84:63-111. Elsevier Academic Press Inc., San Diego.
44. Taubes G. The bacteria fight back. Science 2008, 321:356-361.
45. Tolia N.H., Joshua-Tor L. Strategies for protein coexpression in Escherichia coli. Nature Methods 2006, 3:55-64.
46. Vaney M.C., Maignan S., RiesKautt M., Ducruix A. High-resolution structure (1.33 angstrom) of a HEW lysozyme tetragonal crystal grown in the APCF apparatus. Data and structural comparison with a crystal grown under microgravity from SpaceHab-01 mission. Acta Crystallographica. Section D, Biological Crystallography 1996, 52:505-517.
47. Vocadlo D.J., Davies G.J., Laine R., Withers S.G. Catalysis by hen egg-white lysozyme proceeds via a covalent intermediate. Nature 2001, 412:835-838.
48. Walton T.A., Sousa M.C. Crystal structure of Skp, a prefoldin-like chaperone that protects soluble and membrane proteins from aggregation. Molecular Cell 2004, 15:367-374.
49. Wei J.T., Tang C.D., Wu M.C., Liu G.L., Shi H.L., Li J.F. Cloning and functional expression of a human lysozyme gene (hly) from human leukocytes in Pichia pastoris. Molecular Medicine Reports 2012, 6:173-178.
50. Wilken L.R., Nikolov Z.L. Process evaluations and economic analyses of recombinant human lysozyme and hen egg-white lysozyme purifications. Biotechnology Progress 2011, 27:733-743.
51. Yang B., Wang J., Tang B., Liu Y., Guo C., Yang P., Yu T., Li R., Zhao J., Zhang L., Dai Y., Li N. Characterization of bioactive recombinant human lysozyme expressed in milk of cloned transgenic cattle. PLoS One 2011, 6:e17593.
52. Yu Z., Meng Q., Yu H., Fan B., Yu S., Fei J., Wang L., Dai Y., Li N. Expression and bioactivity of recombinant human lysozyme in the milk of transgenic mice. Journal of Dairy Science 2006, 89:2911-2918.